Neurofilament Light Chain and Glial Fibrillary Acidic Protein as Biomarkers in Primary Open-Angle Glaucoma: Differential Expression in Aqueous Humor and Plasma

Why It Matters

Elevated NfL offers a measurable indicator of neuro‑degeneration in glaucoma, potentially enabling earlier detection and targeted treatment, which could shift clinical practice and drive diagnostic‑tool markets.

Key Takeaways

• NfL levels rise in both aqueous humor and plasma of POAG patients
• GFAP levels show no significant difference between POAG and cataract controls
• Study used ultra‑sensitive SIMOA assay to quantify biomarkers
• NfL may serve as a diagnostic biomarker for glaucoma progression
• Weak, non‑significant correlation observed between aqueous and plasma GFAP

Pulse Analysis

Glaucoma remains a leading cause of irreversible blindness, and clinicians have long sought reliable molecular signals that reflect retinal ganglion cell loss before visual field defects become apparent. Biomarkers such as neurofilament light chain, a structural protein released during axonal injury, have gained traction in neuro‑degenerative fields like multiple sclerosis and Alzheimer’s disease. Translating this concept to ophthalmology could fill a critical gap in early‑stage disease identification, where current imaging and functional tests often lag behind underlying pathology.

In the recent comparative study, investigators applied the single‑molecule array (SIMOA) platform—renowned for its femtomolar sensitivity—to quantify NfL and GFAP in both aqueous humor and peripheral blood. The data revealed a clear elevation of NfL in POAG patients, whereas GFAP, an astrocytic injury marker, remained statistically unchanged. This differential expression underscores that axonal degeneration, rather than glial activation, dominates the early molecular landscape of open‑angle glaucoma. The weak correlation between ocular and systemic GFAP further suggests compartmentalized pathology, reinforcing the specificity of NfL as a cross‑compartment indicator.

From a business perspective, the validation of NfL as a glaucoma biomarker could catalyze a new segment of point‑of‑care diagnostic kits and companion‑test services. Companies specializing in liquid‑biopsy technologies may leverage existing SIMOA infrastructure to expand into ophthalmic applications, while insurers could eventually reimburse biomarker‑guided screening programs. Moreover, pharmaceutical developers targeting neuro‑protective pathways will benefit from an objective endpoint to assess drug efficacy in clinical trials, potentially accelerating time‑to‑market for next‑generation glaucoma therapies.